A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06178991 |
Recruitment Status :
Recruiting
First Posted : December 21, 2023
Last Update Posted : April 18, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and caregivers in terms of simple and easy care. Around 9000 participants will be assigned into 1 of 4 vaccination groups (Group A, B, C or D) by chance.
Cohort 1: Around 4500 participants will be assigned by chance to one of the following:
- Group A:Influenza and COVID-19 combination A vaccine, given at the same time in the right arm and placebo (an injection consisting of just salt water and no medicines in it) in the left arm.
- Group B: COVID-19 vaccine, given at the same time to the right arm and licensed influenza vaccine in the left arm.
Cohort 2: Around 4500 participants will be assigned by chance to one of the following:
- Group C: Influenza and COVID-19 combination B vaccine, given at the same time in the right arm and placebo in the left arm.
- Group D: COVID-19 vaccine, given at the same time in the right arm and licenced influenza vaccine in the left arm.
All participants will receive 2 injections as per their assigned study group at Visit 1. The participants will be followed for about 6 months. During this time, the study will compare participant experiences when they receive a combined vaccination to when they receive separate vaccinations. This will help understand if the study medicine is safe.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Influenza COVID-19 | Biological: Influenza and COVID-19 Combination A Biological: Licensed influenza vaccine Biological: COVID-19 Vaccine Biological: Influenza and COVID-19 Combination B Biological: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 7500 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Masking Description: | This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but all other study personnel, including the principal investigator, and the participant, will be blinded. |
Primary Purpose: | Prevention |
Official Title: | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS |
Actual Study Start Date : | December 20, 2023 |
Estimated Primary Completion Date : | December 5, 2024 |
Estimated Study Completion Date : | December 5, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1 Arm A: Influenza and COVID-19 Combination A and Placebo
Cohort 1 Arm A: Influenza and COVID-19 combination A vaccine and Placebo
|
Biological: Influenza and COVID-19 Combination A
Combined influenza and Pfizer-BioNTech COVID-19 Vaccine Biological: Placebo Saline Solution |
Active Comparator: Cohort 1 Arm B: COVID-19 vaccine and licensed influenza vaccine concomitant administration group
Cohort 1 Arm B: COVID-19 vaccine and licensed influenza vaccine concomitant administration group
|
Biological: Licensed influenza vaccine
Licensed influenza vaccine Biological: COVID-19 Vaccine Pfizer-BioNTech COVID-19 vaccine |
Experimental: Cohort 2 Arm C:Influenza and COVID-19 Combination B and Placebo
Cohort 2 Arm C: Influenza and COVID-19 Combination B vaccine and Placebo
|
Biological: Influenza and COVID-19 Combination B
Combined influenza and Pfizer-BioNTech COVID-19 vaccine Biological: Placebo Saline Solution |
Active Comparator: Cohort 2 Arm D: COVID-19 vaccine and licensed influenza vaccine concomitant administration group
Cohort 2 Arm D: COVID-19 vaccine and licensed influenza vaccine concomitant administration group
|
Biological: Licensed influenza vaccine
Licensed influenza vaccine Biological: COVID-19 Vaccine Pfizer-BioNTech COVID-19 vaccine |
- Percentage of participants reporting prompted local reactions within 7 days following investigational product administration in the right deltoid [ Time Frame: Day 7 ]Describe prompted local reactions following investigational product administration
- Percentage of participants reporting prompted systemic events within 7 days following investigational product administration [ Time Frame: Day 7 ]Describe prompted systemic events following investigational product administration
- Percentage of participants reporting adverse events (AEs) through 4 weeks following investigational product administration [ Time Frame: 4 weeks after vaccination ]Describe AEs occurring through 4 weeks following administration of investigational product
- Percentage of participants reporting serious adverse events (SAEs) through 6 months following investigational product administration [ Time Frame: 6 months after vaccination ]Describe SAEs through 6 months following administration of investigational product
- GMR of HAI titers in Influenza and COVID-19 combination A recipients compared to licensed influenza vaccine recipients 4 weeks after vaccination [ Time Frame: 4 weeks after vaccination ]To demonstrate that the immune response elicited by Influenza and COVID-19 combination A is noninferior to that elicited by licensed influenza vaccine and COVID-19 concomitant administration group
- The difference in percentage of participants achieving seroconversion at 4 weeks after vaccination in Influenza and COVID-19 combination A recipients compared to licensed influenza vaccine recipients [ Time Frame: 4 weeks after vaccination ]To demonstrate that the immune response elicited by Influenza and COVID-19 combination A is noninferior to that elicited by Licensed influenza vaccine and COVID-19 concomitant administration group.
- GMR of SARS-CoV-2-neutralizing titers in Influenza and COVID-19 combination A recipients compared to participants having received licensed influenza vaccine and COVID-19 concomitant administration group at 4 weeks after vaccination [ Time Frame: 4 weeks after vaccination ]To demonstrate that the immune response elicited by Influenza and COVID-19 combination A is noninferior to that elicited by COVID-19 administered concomitantly with licensed influenza vaccine
- The difference in percentages of subjects with seroresponse at 4 weeks after vaccination in Influenza and COVID-19 combination A recipients compared to subjects having received licensed influenza vaccine and COVID-19 concomitant administration group [ Time Frame: 4 weeks after vaccination ]To demonstrate that the immune response elicited by Influenza and COVID-19 combination A is noninferior to that elicited by COVID-19 administered concomitantly with licensed influenza vaccine
- GMR of HAI titers in Influenza and COVID-19 combination B recipients compared to licensed influenza vaccine recipients 4 weeks after vaccination [ Time Frame: 4 weeks after vaccination ]To demonstrate that the immune response elicited by Influenza and COVID-19 combination B is noninferior to that elicited by licensed influenza vaccine administered concomitantly with COVID-19
- The difference in percentage of participants achieving seroconversion at 4 weeks after vaccination in Influenza and COVID-19 combination B recipients compared to licensed influenza vaccine recipients [ Time Frame: 4 weeks after vaccination ]To demonstrate that the immune response elicited by Influenza and COVID-19 combination B is noninferior to that elicited by licensed influenza vaccine administered concomitantly with COVID-19
- GMR of SARS-CoV-2-neutralizing titers in Influenza and COVID-19 combination B recipients compared to participants having received licensed influenza vaccine concurrently in the deltoid opposite to that used for COVID-19 at 4 weeks after vaccination [ Time Frame: 4 weeks after vaccination ]To demonstrate that the immune response elicited by Influenza and COVID-19 combination B is noninferior to that elicited by COVID-19 administered concomitantly with licensed influenza vaccine
- The difference in percentages of subjects with seroresponse at 4 weeks after vaccination in influenza and COVID-19 combination B recipients compared to subjects having received licensed influenza vaccine concurrently with COVID-19 [ Time Frame: 4 weeks after vaccination ]To demonstrate that the immune response elicited by Influenza and COVID-19 combination B is noninferior to that elicited by COVID-19 administered concomitantly with licensed influenza vaccine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Participants 18 through 64 years of age (or the minimum age of consent in accordance with local regulations) at Visit 1.
- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
Exclusion Criteria:
- Vaccination with any investigational or licensed influenza vaccine within 6 months (175 days) before study intervention administration, or ongoing receipt of chronic antiviral therapy with activity against influenza.
- Vaccination with any investigational or licensed COVID-19 vaccine within 6 months (175 days) before study intervention administration.
Please refer to the study contact for further eligibility details
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06178991
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | BioNTech SE |
ClinicalTrials.gov Identifier: | NCT06178991 |
Other Study ID Numbers: |
C5261002 |
First Posted: | December 21, 2023 Key Record Dates |
Last Update Posted: | April 18, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Influenza, Human Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases Coronavirus Infections Coronaviridae Infections |
Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Orthomyxoviridae Infections Vaccines Immunologic Factors Physiological Effects of Drugs |